Preventing acute antibody-driven kidney transplant rejection
Acute Antibody Mediated Kidney Allograft Rejection
['FUNDING_R01'] · CLEVELAND CLINIC LERNER COM-CWRU · NIH-11168976
The team is testing ways to stop immune cells from causing early rejection in people who receive kidney transplants.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CLEVELAND CLINIC LERNER COM-CWRU (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-11168976 on ClinicalTrials.gov |
What this research studies
From a patient's view, researchers are studying why some immune-depleting treatments leave behind memory immune cells that can spark early transplant rejection. They use laboratory models and tissue studies to follow how B cells and inflammatory signals (like IL-1β, IL-6, IL-27) help those T cells recover after treatment. The group is probing innate immune sensors (TLR4, TLR9, and Mincle) that trigger B cell inflammation and looking for approaches that favor healthy new T cell production from the thymus instead of harmful expansion. The work builds on earlier animal findings to guide therapies that might reduce over-immunosuppression while protecting the graft.
Who could benefit from this research
Good fit: People who have recently received a kidney transplant, especially those treated with lymphocyte-depleting drugs such as ATG, would be the most relevant candidates for related clinical follow-up or sample donation.
Not a fit: People without a kidney transplant or those not treated with lymphocyte-depleting therapies are unlikely to receive direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could lower the risk of early kidney transplant rejection and reduce the need for very strong, long-term immune suppression.
How similar studies have performed: Previous animal studies have shown memory T cells and B-cell cytokines drive rebound immune responses after depletion, but translating interventions to human transplant patients remains limited.
Where this research is happening
CLEVELAND, UNITED STATES
- CLEVELAND CLINIC LERNER COM-CWRU — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FAIRCHILD, ROBERT L — CLEVELAND CLINIC LERNER COM-CWRU
- Study coordinator: FAIRCHILD, ROBERT L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.